收藏切换
Advances in anti-tumor research of HDAC inhibitors and combination with PI3K inhibitors
收藏切换
PDF
Lei HUANG, Xiao-guang CHEN*, Fang-fang LAI*
Acta Pharmaceutica Sinica | 2022, 57(12) : 3557 - 3563
Less
收藏切换
Acta Pharmaceutica Sinica | 2022, 57(12): 3557-3563
Reviews
Advances in anti-tumor research of HDAC inhibitors and combination with PI3K inhibitors
Full
Lei HUANG, Xiao-guang CHEN*, Fang-fang LAI*
Affiliations
  • State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Published: 2022-12-12 doi: 10.16438/j.0513-4870.2022-0672
Outline
收藏切换

Histone deacetylase (HDAC) is usually abnormally overexpressed, which mainly leads to the transcriptional repression of tumor suppressor genes. Histone deacetylase inhibitors (HDIs) exert anti-tumor biological effects by regulating nucleosome structure, inhibiting HDAC activity, and controlling the expression of tumor suppressor genes. There are currently 5 drugs on the market, but only for peripheral T-cell lymphoma and cutaneous T-cell lymphoma. In solid tumors, most of the HDAC inhibitors used have failed to achieve effective therapeutic effects. Phosphoinositide 3-kinase (PI3K) is the starting node of the PI3K-AKT-mTOR signaling pathway, which plays a very important role in the proliferation, migration, invasion, and differentiation of tumor cells. The abnormal activation of PI3K is closely related to the occurrence and development of tumors, and the combined use of HDAC and PI3K inhibitors and HDAC/PI3K dual-target inhibitors show synergistic anticancer activity. This article introduces the anti-tumor clinical and preclinical research progress of representative HDAC inhibitors and PI3K inhibitors, as well as HDAC/PI3K dual-target inhibitors.

HDAC inhibitor  /  PI3K inhibitor  /  combination therapy  /  HDAC/PI3K dual-target inhibitor  /  anti-tumor
Lei HUANG, Xiao-guang CHEN, Fang-fang LAI. Advances in anti-tumor research of HDAC inhibitors and combination with PI3K inhibitors[J]. Acta Pharmaceutica Sinica, 2022 , 57 (12) : 3557 -3563 . DOI: 10.16438/j.0513-4870.2022-0672
Year 2022 volume 57 Issue 12
PDF
344
146
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2022-0672
  • Receive Date:2022-05-29
  • Online Date:2025-12-24
  • Published:2022-12-12
Article Data
Affiliations
History
  • Received:2022-05-29
  • Revised:2022-07-10
Funding
Affiliations
    State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2022-0672
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT